Mermaid Bio GmbH
Mermaid Bio’s mission is to discover and develop breakthrough intrabodies (antibodies for intracellular targets) to treat unmet patient needs. We link single domain antibodies (nanobodies) together with advancements in drug delivery (using mRNA/LNP systems) to create a proprietary platform capable of producing breakthrough medicines.
Mermaid Bio GmbH
Mermaid Bio delivers targeted drug delivery using intrabodies, focusing on diseases like Hepatocellular Carcinoma.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
Licensing of Intrabody technology
Licensing of single-domain antibodies (sdAbs)
Licensing of targeted delivery systems
mRNA delivery technology
Lipid nanoparticle encapsulation technology
AI Insights
Growth Trajectory
Due to its liquidation, Mermaid Bio's growth trajectory is currently stalled, dependent on acquisition or licensing of its assets.
Market Opportunity
Mermaid Bio's market opportunity lies in the licensing of their intrabody technology for targeted drug delivery to other biotech or pharmaceutical companies.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats